Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study

被引：0
|
作者：
Antoinette MaassenVanDenBrink
Gisela M. Terwindt
Joshua M. Cohen
Steve Barash
Verena Ramirez Campos
Maja Galic
Xiaoping Ning
Mikko Kärppä
机构：
[1] Erasmus University Medical Center Rotterdam,Division of Pharmacology and Vascular Medicine, Department of Internal Medicine
[2] Leiden University Medical Center,Department of Neurology
[3] Teva Pharmaceutical Products R&D,Research Unit of Clinical Neuroscience
[4] Inc.,undefined
[5] Teva Pharmaceuticals Europe B.V.,undefined
[6] University of Oulu and Medical Research Center,undefined
[7] Oulu University Hospital,undefined
来源：
The Journal of Headache and Pain | 2021年 / 22卷
关键词：
Fremanezumab; Calcitonin gene-related peptide; Age; Sex; Migraine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Efficacy of Fremanezumab by Prior Number of Preventive Treatments With Inadequate Response in Patients With Episodic Migraine and Chronic Migraine: Results of the International, Multicenter Phase 3b
    Pazdera, L.
    Cohen, J. M.
    Ning, X.
    Ramirez-Campos, V
    Yang, R.
    HEADACHE, 2020, 60 : 13 - 14
  • [32] Treatment of difficult-to-treat-dermatophytosis: results of a randomized, double-blind, placebo-controlled study
    Fonseka, Sanjeewani
    Bandara, Dilan Dileepa Jayarathne
    Wickramaarachchi, Dasun Chathumina
    Narankotuwa, Narankotuwe Gedara Kumudu Hasanka Heshani
    Kumarasiri, Pallegoda Vithana Ranjith
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2021, 15 (11): : 1731 - 1737
  • [33] Efficacy and Safety of Secukinumab in Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Randomized, Placebo-controlled Phase 3b Trial
    Behrens, Frank
    Sewerin, Philipp
    De Miguel, Eugenio
    Patel, Yusuf
    Batalov, Anastas
    Dokoupilova, Eva
    Kleinmond, Christine
    Pournara, Effie
    Shekhawat, Ankita
    Jentzsch, Claudia
    Wiedon, Annette
    Baraliakos, Xenofon
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [34] EFFICACY IN PATIENTS SWITCHING FROM QUARTERLY TO MONTHLY FREMANEZUMAB OR MAINTAINED ON MONTHLY FREMANEZUMAB TREATMENT OVER 6 MONTHS IN THE PHASE 3B FOCUS STUDY
    Gladstone, Jonathan
    Diener, Hans-Christoph
    Ning, Xiaoping
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Du, Evelyn
    Spierings, Egilius L. H.
    CEPHALALGIA, 2020, 40 : 83 - 84
  • [35] Efficacy in Patients Switching from Quarterly to Monthly Fremanezumab or Maintained on Monthly Fremanezumab Treatment Over 6 Months in the Phase 3b FOCUS Study
    Gladstone, Jonathan
    Diener, Hans-Christoph
    Ning, Xiaoping
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Du, Evelyn
    Spierings, Egilius L. H.
    NEUROLOGY, 2021, 96 (15)
  • [36] Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
    Takeshima, Takao
    Sakai, Fumihiko
    Hirata, Koichi
    Imai, Noboru
    Matsumori, Yasuhiko
    Yoshida, Ryuji
    Peng, Cheng
    Cheng, Sunfa
    Mikol, Daniel D.
    HEADACHE, 2021, 61 (06): : 927 - 935
  • [37] Clinically Meaningful Responses to Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications in the Randomized, Placebo-Controlled FOCUS Study
    Spierings, Egilius L. H.
    Ning, Xiaoping
    Galic, Maja
    Cohen, Joshua M.
    Yang, Ronghua
    ANNALS OF NEUROLOGY, 2019, 86 : S168 - S168
  • [38] Effect of Fremanezumab on the Total Burden of Migraine in Patients with Episodic or Chronic Migraine: Findings from 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
    Sun-Edelstein, Christina
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Barash, Steve
    Brandes, Jan Lewis
    NEUROLOGY, 2021, 96 (15)
  • [39] Efficacy With Fremanezumab in Migraine Patients With Comorbid Moderate to Severe Depression and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Treatments: Subgroup Analysis of the Randomized, Placebo-controlled FOCUS Study
    Buse, Dawn
    Cohen, Joshua
    Ramirez-Campos, Verena
    Yang, Ronghua
    Ning, Xiaoping
    Galic, Maja
    Lipton, Richard B.
    NEUROLOGY, 2020, 94 (15)
  • [40] Efficacy with Fremanezumab in Migraine Patients with Comorbid Moderate to Severe Depression and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Treatments: Subgroup Analysis of the Randomized, Placebo-Controlled FOCUS Study
    Lipton, Richard B.
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Yang, Ronghua
    Ning, Xiaoping
    Galic, Maja
    Buse, Dawn C.
    ANNALS OF NEUROLOGY, 2020, 88 : S159 - S160
12345